RedHill Biopharma Announces Initiation of Phase II Study with YELIVATM in Hepatocellular Carcinoma at the Medical University of South Carolina

The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVATMÂABC294640 in patients with advanced hepatocellular carcinoma HCC the most common primary malignant cancer of the liver with a worldwide mortality rate of 95 The...